Special Issue "Protein Kinases: Signalling and Disease"
Deadline for manuscript submissions: closed (31 May 2020).
Interests: protein kinase signaling; protein kinases as therapeutic targets; parasitic protein kinases
Protein kinases have become a major drug target for the treatment of a variety of diseases, especially cancer. Kinase inhibitors have been approved for a number of therapeutic indications and will likely continue to expand. One recent example is the small molecule JAK kinase inhibitor, Xeljanz (tofacitinib). Originally approved for the treatment of rheumatoid arthritis in 2012, it has received approval this year (2018) the treatment of ulcerative colitis as well. The list of indications for which kinase inhibitors may find use as therapeutic agents continues to grow, including uses for treating viral and parasitic diseases. This Special Issue focuses on the connection between protein kinase signalling and disease, with an emphasis on novel small molecule inhibitors and new therapeutic indications for these agents.
Prof. John Siekierka
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- protein kinases
- small molecule inhibitors
- novel indications